Gastroesophageal Reflux Disease (GERD) - Drug Pipeline Landscape, 2023
Description
Gastroesophageal Reflux Disease (GERD) or acid reflux is a condition in which the content of the stomach regurgitates (backs up, or refluxes) into the esophagus. The refluxate is usually acidic and can cause inflammation and erosions.
Gastroesophageal reflux disease can cause due to frequent acid reflux or reflux of nonacidic content from the stomach, If the sphincter does not relax as it should or it weakens, stomach acid can flow back into the esophagus. This constant backwash of acid irritates the lining of the esophagus, often causing it to become inflamed.
Symptoms of gastroesophageal reflux disease includes chronic heartburn and acid regurgitation, a burning sensation in chest (heartburn), usually after eating, which might be worse at night or while lying down, upper abdominal or chest pain.
Doctors most often diagnose gastroesophageal reflux disease by asking about symptoms. The tests include ambulatory 24-hour pH probe, esophogram, upper endoscopy, esophageal manometry, esophageal pH monitoring.
The most common investigative treatment include proton pump inhibitors. Symptoms can be eased through lifestyle changes and home remedies like eating smaller and more frequent meals each day instead of a few large meals which promotes digestion and can aid in preventing heartburn, quit smoking, avoid lying down for at least two hours after a meal or after drinking acidic beverages, like soda, or other caffeinated beverages.
Report Highlights
Global Insight Service’s, Gastroesophageal Reflux Disease (GERD) - Drug Pipeline Landscape, 2023 report provides an overview of the Gastroesophageal Reflux Disease (GERD) pipeline drugs. This report covers detailed insights on Gastroesophageal Reflux Disease (GERD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Gastroesophageal Reflux Disease (GERD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Gastroesophageal reflux disease can cause due to frequent acid reflux or reflux of nonacidic content from the stomach, If the sphincter does not relax as it should or it weakens, stomach acid can flow back into the esophagus. This constant backwash of acid irritates the lining of the esophagus, often causing it to become inflamed.
Symptoms of gastroesophageal reflux disease includes chronic heartburn and acid regurgitation, a burning sensation in chest (heartburn), usually after eating, which might be worse at night or while lying down, upper abdominal or chest pain.
Doctors most often diagnose gastroesophageal reflux disease by asking about symptoms. The tests include ambulatory 24-hour pH probe, esophogram, upper endoscopy, esophageal manometry, esophageal pH monitoring.
The most common investigative treatment include proton pump inhibitors. Symptoms can be eased through lifestyle changes and home remedies like eating smaller and more frequent meals each day instead of a few large meals which promotes digestion and can aid in preventing heartburn, quit smoking, avoid lying down for at least two hours after a meal or after drinking acidic beverages, like soda, or other caffeinated beverages.
Report Highlights
Global Insight Service’s, Gastroesophageal Reflux Disease (GERD) - Drug Pipeline Landscape, 2023 report provides an overview of the Gastroesophageal Reflux Disease (GERD) pipeline drugs. This report covers detailed insights on Gastroesophageal Reflux Disease (GERD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Gastroesophageal Reflux Disease (GERD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
85 Pages
- List of Tables
- List of Figures
- 1. Introduction
- 1.1 Gastroesophageal Reflux Disease (GERD) – Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview – Gastroesophageal Reflux Disease (GERD)
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Gastroesophageal Reflux Disease (GERD) – Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Late-Stage Drugs - Pre-Registration
- 5.1.1 DWP14012
- 5.1.2 IN-C004
- 5.1.3 KFP-H008
- 5.2 Clinical Stage Drugs - Phase III
- 5.2.1 BLI5100
- 5.2.2 OCN-101
- 5.2.3 Vonoprazan
- 5.3 Clinical Stage Drugs - Phase II
- 5.3.1 Naronapride
- 5.3.2 X842
- 5.4 Clinical Stage Drugs - Phase I
- 5.4.1 AD-212
- 5.4.2 AD-213
- 5.4.3 AD-214
- 5.4.4 Anaprazole Sodium
- 5.4.5 Dexlansoprazole (Pediatric)
- 5.4.6 IN-C001
- 5.4.7 IN-C005
- 5.5 Early-Stage Drugs - Preclinical
- 5.5.1 Drug for GERD
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Addpharma Inc
- 9.2 Cinclus Pharma AG
- 9.3 Daewoong Pharmaceutical Co LTD
- 9.4 Hana Pharm Co Ltd
- 9.5 HK inno.N Corp
- 9.6 Jiangsu Carephar Pharmaceutical Co Ltd
- 9.7 Onconic Therapeutics Inc
- 9.8 Phathom Pharmaceuticals, Inc
- 9.9 Renexxion LLC
- 9.10 Sebela Pharmaceuticals
- 9.11 Takeda
- 9.12 Xuanzhu Biopharmaceutical Co Ltd
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products Under development for Gastroesophageal Reflux Disease (GERD)
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - BLI5100/Sebela Pharmaceuticals
- Table 2.2 Clinical Trial Details - OCN-101/Onconic Therapeutics Inc
- Table 2.3 Clinical Trial Details - Vonoprazan/Phathom Pharmaceuticals, Inc
- Table 2.4 Clinical Trial Details - X842/Cinclus Pharma AG
- Table 2.5 Clinical Trial Details - AD-213/Addpharma Inc
- Table 2.6 Clinical Trial Details - AD-214/Addpharma Inc
- Table 2.7 Clinical Trial Details - Anaprazole Sodium/Xuanzhu Biopharmaceutical Co Ltd
- Table 2.8 Clinical Trial Details - Dexlansoprazole (Pediatric)/Takeda
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Gastroesophageal Reflux Disease (GERD), 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Gastroesophageal Reflux Disease (GERD), 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Gastroesophageal Reflux Disease (GERD), 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Gastroesophageal Reflux Disease (GERD), 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Gastroesophageal Reflux Disease (GERD), 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
